---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-025262"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:03:38.231620+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie names Robert Michael as CEO effective July 1; Gonzalez to executive chairman

## Summary
- Robert A. Michael, current president & COO, will become CEO on July 1, 2024.
- Richard A. Gonzalez retires as CEO after 11 years, becomes executive chairman.
- Michael appointed to board as Class II director, effective July 1, 2024.
- Gonzalez to remain as executive chairman; board conducted thorough succession process.
- Michael played key role in Allergan, ImmunoGen, and pending Cerevel acquisitions.

## SEC filing metadata
- accession: 0001104659-24-025262
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-025262
- JSON: https://secwatch.observer/filing/0001104659-24-025262.json
- Plain text: https://secwatch.observer/filing/0001104659-24-025262.txt

## Key facts
- Executive change
  Robert A. Michael was appointed as Director at AbbVie Inc..
  - Action: appointed
  - Role: Director
  source text: The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm
- Executive change
  Richard A. Gonzalez changed role as Executive Chairman at AbbVie Inc..
  - Action: become
  - Role: Executive Chairman
  source text: Mr. Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role of CEO and become Executive Chairman of the Board of Directors, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.